Large-scale biologics infrastructure project in Ahmedabad Kashiv BioSciences has secured 648 crore INR (approximately $77 million) in financing from the Union Bank of India. The funds will be allocated to expanding its biopharmaceutical manufacturing infrastructure in Pipan, near Ahmedabad, Gujarat. The project focuses on developing a state-of-the-art single-use commercial manufacturing facility. Once fully operational, the plant is expected to have a capacity of up to 50,000 liters, making it one of the largest biologics production sites of its kind in India.
Enhancing competitiveness in international markets The facility expansion is a core part of Kashiv’s strategy to strengthen its global footprint and position India as a hub for advanced pharmaceutical production. The new site will be equipped with cutting-edge technologies to produce high-quality biosimilars and specialty pharmaceuticals. This initiative aims to improve the company’s competitiveness in highly regulated markets, including the United States, Canada, and Europe, while creating numerous high-value jobs across scientific, technical, and operational roles.
Synergy with development support policies The financing aligns with policy support from the Gujarat state government through the Gujarat State Biotechnology Mission (GSBTM), which offers incentives for advanced biotech investments. Kashiv BioSciences, a subsidiary of U.S.-based Kashiv BioSciences LLC, is among a limited number of firms capable of both manufacturing and holding marketing authorizations for several biosimilars. The project is expected to accelerate innovation, broaden access to high-quality biologics, and bolster India’s role in global healthcare supply chains.